Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.23%
SPX
-1.60%
IXIC
-2.24%
FTSE
-0.70%
N225
-0.66%
AXJO
-0.92%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

RDNT is now overvalued and could go down -32%

Jun 24, 2025, 12:00 PM
6.75%
What does RDNT do
RadNet, headquartered in Los Angeles, operates 366 outpatient diagnostic imaging centers across the U.S. and employs 7,872 people, offering various imaging services and developing AI applications for enhanced diagnostics.
Based on our analysis, Radnet has received an overvalued rating of 1 out of 5 stars from Cashu. While the company shows some strengths, several key financial ratios suggest it is not as attractive as it may seem compared to its sector. One critical metric is the Price-to-Book (PB) Ratio, which stands at 5.73 for Radnet, significantly higher than the sector average of 2.71. A higher PB ratio can indicate that a stock is overpriced relative to its book value, signaling potential overvaluation. Additionally, Radnet's Return on Assets (ROA) Ratio is 0.08, while the sector average is -47.59. Although Radnet shows a positive ROA, this figure still suggests that the company is not utilizing its assets as effectively as its peers, raising concerns about operational efficiency. Furthermore, the company’s Return on Equity (ROE) Ratio is 0.31, compared to a sector average of -76.41. While Radnet's ROE is positive, it signals that investors may not be receiving returns that justify its current stock price relative to others in the sector. Overall, while Radnet shows a strong net profit margin of 0.15 against a sector average of -137.57, the high PB Ratio and the relatively low ROA and ROE ratios indicate that the stock may be overpriced. Investors should consider these factors when evaluating Radnet’s current market valuation. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!